(-0.54%) 4 983.94 points
(0.57%) 37 989 points
(-1.46%) 15 374 points
(1.09%) $83.63
(-0.17%) $1.754
(0.70%) $2 414.70
(1.60%) $28.84
(-1.09%) $944.10
(-0.08%) $0.939
(-0.16%) $11.02
(0.46%) $0.808
(-0.91%) $93.05
@ €86.64
Issued: 19 Apr 2024 @ 11:05
Return: -0.02%
Previous signal: Apr 18 - 15:54
Previous signal:
Return: 0.37 %
Live Chart Being Loaded With Signals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...
Stats | |
---|---|
Today's Volume | 273 925 |
Average Volume | 626 491 |
Market Cap | 20.59B |
EPS | €0 ( 2024-03-20 ) |
Next earnings date | ( €-0.690 ) 2024-05-06 |
Last Dividend | €2.11 ( 2022-06-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.28 |
ATR14 | €1.955 (2.26%) |
Volume Correlation
BioNTech SE Correlation
10 Most Positive Correlations | |
---|---|
VERB | 0.95 |
OPINL | 0.946 |
BNGO | 0.944 |
VRAY | 0.944 |
AUDC | 0.942 |
NESR | 0.939 |
EGBN | 0.939 |
CNXC | 0.938 |
MAGS | 0.938 |
AGIL | 0.938 |
10 Most Negative Correlations | |
---|---|
XPDB | -0.94 |
ITAQ | -0.939 |
SWAV | -0.937 |
ROCL | -0.935 |
ATEC | -0.934 |
FTPA | -0.932 |
TIOA | -0.931 |
ROC | -0.931 |
CBRG | -0.93 |
BRIVU | -0.929 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioNTech SE Correlation - Currency/Commodity
BioNTech SE Financials
Annual | 2023 |
Revenue: | €3.82B |
Gross Profit: | €3.22B (84.29 %) |
EPS: | €3.79 |
Q4 | 2023 |
Revenue: | €1.48B |
Gross Profit: | €1.30B (87.89 %) |
EPS: | €1.880 |
Q3 | 2023 |
Revenue: | €895.30M |
Gross Profit: | €235.60M (26.32 %) |
EPS: | €0.690 |
Q2 | 2023 |
Revenue: | €167.70M |
Gross Profit: | €-368.60M (-219.80 %) |
EPS: | €-0.790 |
Financial Reports:
No articles found.
BioNTech SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €2.11 | 2022-06-02 |
Last Dividend | €2.11 | 2022-06-02 |
Next Dividend | €0 | N/A |
Payout Date | 2022-06-17 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €2.11 | -- |
Avg. Dividend % Per Year | 0.15% | -- |
Score | 1.89 | -- |
Div. Sustainability Score | 9.73 | |
Div.Growth Potential Score | 2.39 | |
Div. Directional Score | 6.06 | -- |
Year | Amount | Yield |
---|---|---|
2022 | €2.11 | 0.91% |
2023 | €0 | 0.00% |
2024 | €0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.244 | 1.500 | 5.13 | 7.69 | [0 - 0.5] |
returnOnAssetsTTM | 0.0404 | 1.200 | 8.65 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0464 | 1.500 | -0.596 | -0.894 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.12 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00952 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.58 | 1.000 | 9.04 | 9.04 | [3 - 30] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 0.186 | 0.373 | [0 - 20] |
debtEquityRatioTTM | 0.0108 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.527 | 1.000 | 4.54 | 4.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.38 | 8.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 24.52 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.166 | 0.800 | -2.23 | -1.781 | [0.5 - 2] |
Total Score | 9.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.08 | 1.000 | 7.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0464 | 2.50 | -0.383 | -0.894 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 3.46 | 0.373 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 1.406 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.39 |
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators